Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
AssigneeAllergan, Inc.
InventorsRichard L. Beard, John E. Donello, Veena Viswanath, Michael E. Garst, Haiqing Yuan, Xiaoxia Liu
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation.
Claims13
A compound represented by Formula I, an enantiomer, a diastereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R2 is —S—, —S(O)—, or —S(O)2—;
- R3 is CR7, N or N-oxide;
- R4 is CR7, N or N-oxide;
- R5 is CR7, N or N-oxide;
- R6 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R7 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR19R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
- R8 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R9 is H, hydroxyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R10 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R11 can form a 3-10 membered ring;
- R11 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R10 can form a 3-10 membered ring;
- R12 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
- with the provisios
- at least one of R3, R4 or R5 is N or N-oxide;
- and,
- R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.
A method of treating a disorder associated with chemokine receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- wherein:
- R1 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R2 is —S—, —S(O)—, or —S(O)2—;
- R3 is CR7, N or N-oxide;
- R4 is CR7, N or N-oxide;
- R5 is CR7, N or N-oxide;
- R6 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R7 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
- R8 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R9 is H, hydroxyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl or is substituted or unsubstituted C6-10 aryl;
- R10 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R11 can form a 3-10 membered ring;
- R11 is H, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, is substituted or unsubstituted C6-10 aryl or together with R19 can form a 3-10 membered ring;
- R12 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OR8, C2-6 alkenyl, C2-6 alkynyl, CN, C(O)R9, NR10R11, amide, urea, sulfonamide, sulfone, sulfoxide, sulfide, sulfonic acid, nitro, phosphate or phosphonic acid;
- with the provisios
- at least one of R3, R4 or R5 is N or N-oxide;
- and,
- R1 is not benzofuran-2-yl, when R3 is CR7 and R4 is CR7 and R5 is N.
Dependencies are inferred from the claim text.